Galderma Expands Relfydess Reach With China Approval For Frown Lines
Galderma (GDERF) received China approval for Relfydess, a neuromodulator for frown lines. Supported by clinical data, it's the first ready-to-use liquid in China. The approval expands Galderma's portfolio in a growing market. GDERF stock closed at $220.14, up 10.82%.
